File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: 7α-Methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men

Title7α-Methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men
Authors
Issue Date1999
PublisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org
Citation
Journal Of Clinical Endocrinology And Metabolism, 1999, v. 84 n. 10, p. 3556-3562 How to Cite?
AbstractThe synthetic steroid 7α-methyl-19-nortestosterone (MENT) is a potent androgen that is resistant to 5α-reductase. It thus has decreased activity at the prostate and may have advantages over testosterone-based regimens in long term treatment or as part of a male contraceptive. Administration to eugonadal men results in suppression of gonadotropins, but its ability to support androgen-dependent behavior has not been investigated. For sustained release administration, MENT acetate was used, because its diffusion characteristics were more suitable for use in implants. However, upon release the acetate is rapidly hydrolyzed, and MENT is the biologically active moiety in circulation. We studied the effects of MENT on sexual interest and activity, spontaneous erection, and mood states in comparison with testosterone enanthate (TE) in 20 Caucasian and Chinese hypogonadal men recruited in Edinburgh and Hong Kong (n = 10 in each center). Outcomes were measured using a combination of daily diaries, semistructured interviews, and questionnaires. Nocturnal penile tumescence (NPT) was also recorded in the Edinburgh group. After withdrawal of androgen replacement treatment (wash-out phase) for a minimum of 6 weeks, subjects were randomized to two groups in a cross-over design. Drug treatment regimens were of 6-week duration and consisted of two implants, each containing 115 mg MENT acetate, inserted sc into the upper arm and removed after 6 weeks and two injections of TE (200 mg, im) 3 weeks apart. MENT treatment resulted in stable plasma MENT concentrations of 1.4 ± 0.1 nmol/L after 3 weeks and 1.3 ± 0.1 nmol/L after 6 weeks (mean ± SEM; all men). Nadir testosterone concentrations were 3,6 ± 0.6 nmol/L at the end of the wash-out phase and 9.4 ± 0.6 nmol/L 3 weeks after each injection. There were no differences in hormone concentrations between centers. There were no adverse toxicological effects. There were only minor differences between the two treatments. Both MENT and TE treatment resulted in significant increases in sexual interest and activity, spontaneous erection (both by self-report and NPT measurement), and increases in positive moods, with decreases in negative moods in the Edinburgh group. In the Hong Kong group, both treatments increased waking erection, with a trend toward increased sexual interest and activity. Mood states appeared to be less affected during the wash-out phase than in Edinburgh men and showed no significant response to either treatment. These results demonstrate that MENT has similar effects on sexual activity and mood states as testosterone in hypogonadal men. As NPT is a physiological androgen-dependant outcome, these data provide further evidence for the androgenicity of MENT. The lack of detected effect of either androgen in Hong Kong men other than on waking erection illustrates the importance of the cultural context of symptomatology and its measurement. The appropriate dose of MENT remains to be determined, but these results support its development as a potential androgen replacement therapy.
Persistent Identifierhttp://hdl.handle.net/10722/162356
ISSN
2015 Impact Factor: 5.531
2015 SCImago Journal Rankings: 2.940
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorAnderson, RAen_US
dc.contributor.authorMartin, CWen_US
dc.contributor.authorKung, AWCen_US
dc.contributor.authorEverington, Den_US
dc.contributor.authorPun, TCen_US
dc.contributor.authorTan, KCBen_US
dc.contributor.authorBancroft, Jen_US
dc.contributor.authorSundaram, Ken_US
dc.contributor.authorMooYoung, AJen_US
dc.contributor.authorBaird, DTen_US
dc.date.accessioned2012-09-05T05:19:14Z-
dc.date.available2012-09-05T05:19:14Z-
dc.date.issued1999en_US
dc.identifier.citationJournal Of Clinical Endocrinology And Metabolism, 1999, v. 84 n. 10, p. 3556-3562en_US
dc.identifier.issn0021-972Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/162356-
dc.description.abstractThe synthetic steroid 7α-methyl-19-nortestosterone (MENT) is a potent androgen that is resistant to 5α-reductase. It thus has decreased activity at the prostate and may have advantages over testosterone-based regimens in long term treatment or as part of a male contraceptive. Administration to eugonadal men results in suppression of gonadotropins, but its ability to support androgen-dependent behavior has not been investigated. For sustained release administration, MENT acetate was used, because its diffusion characteristics were more suitable for use in implants. However, upon release the acetate is rapidly hydrolyzed, and MENT is the biologically active moiety in circulation. We studied the effects of MENT on sexual interest and activity, spontaneous erection, and mood states in comparison with testosterone enanthate (TE) in 20 Caucasian and Chinese hypogonadal men recruited in Edinburgh and Hong Kong (n = 10 in each center). Outcomes were measured using a combination of daily diaries, semistructured interviews, and questionnaires. Nocturnal penile tumescence (NPT) was also recorded in the Edinburgh group. After withdrawal of androgen replacement treatment (wash-out phase) for a minimum of 6 weeks, subjects were randomized to two groups in a cross-over design. Drug treatment regimens were of 6-week duration and consisted of two implants, each containing 115 mg MENT acetate, inserted sc into the upper arm and removed after 6 weeks and two injections of TE (200 mg, im) 3 weeks apart. MENT treatment resulted in stable plasma MENT concentrations of 1.4 ± 0.1 nmol/L after 3 weeks and 1.3 ± 0.1 nmol/L after 6 weeks (mean ± SEM; all men). Nadir testosterone concentrations were 3,6 ± 0.6 nmol/L at the end of the wash-out phase and 9.4 ± 0.6 nmol/L 3 weeks after each injection. There were no differences in hormone concentrations between centers. There were no adverse toxicological effects. There were only minor differences between the two treatments. Both MENT and TE treatment resulted in significant increases in sexual interest and activity, spontaneous erection (both by self-report and NPT measurement), and increases in positive moods, with decreases in negative moods in the Edinburgh group. In the Hong Kong group, both treatments increased waking erection, with a trend toward increased sexual interest and activity. Mood states appeared to be less affected during the wash-out phase than in Edinburgh men and showed no significant response to either treatment. These results demonstrate that MENT has similar effects on sexual activity and mood states as testosterone in hypogonadal men. As NPT is a physiological androgen-dependant outcome, these data provide further evidence for the androgenicity of MENT. The lack of detected effect of either androgen in Hong Kong men other than on waking erection illustrates the importance of the cultural context of symptomatology and its measurement. The appropriate dose of MENT remains to be determined, but these results support its development as a potential androgen replacement therapy.en_US
dc.languageengen_US
dc.publisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.orgen_US
dc.relation.ispartofJournal of Clinical Endocrinology and Metabolismen_US
dc.rightsJournal of Clinical Endocrinology and Metabolism. Copyright © The Endocrine Society.-
dc.subject.meshAffect - drug effects-
dc.subject.meshHypogonadism - blood - drug therapy - physiopathology - psychology-
dc.subject.meshMasturbation - epidemiology-
dc.subject.meshNandrolone - adverse effects - analogs and derivatives - therapeutic use-
dc.subject.meshSexual Behavior - drug effects-
dc.title7α-Methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal menen_US
dc.typeArticleen_US
dc.identifier.emailKung, AWC:awckung@hku.hken_US
dc.identifier.emailTan, KCB:kcbtan@hku.hken_US
dc.identifier.authorityKung, AWC=rp00368en_US
dc.identifier.authorityTan, KCB=rp00402en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1210/jc.84.10.3556-
dc.identifier.pmid10522995-
dc.identifier.scopuseid_2-s2.0-0033237648en_US
dc.identifier.hkuros48862-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033237648&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume84en_US
dc.identifier.issue10en_US
dc.identifier.spage3556en_US
dc.identifier.epage3562en_US
dc.identifier.isiWOS:000083013300024-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridAnderson, RA=35226078200en_US
dc.identifier.scopusauthoridMartin, CW=7405842668en_US
dc.identifier.scopusauthoridKung, AWC=7102322339en_US
dc.identifier.scopusauthoridEverington, D=35406148300en_US
dc.identifier.scopusauthoridPun, TC=7005509306en_US
dc.identifier.scopusauthoridTan, KCB=8082703100en_US
dc.identifier.scopusauthoridBancroft, J=7102220950en_US
dc.identifier.scopusauthoridSundaram, K=7202825768en_US
dc.identifier.scopusauthoridMooYoung, AJ=6701688761en_US
dc.identifier.scopusauthoridBaird, DT=35371609800en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats